Improvements in drying technologiesefficient solutions for cleaner production with higher energy efficiency and reduced emission
Side Effects & Safety Considerations The adverse event profile of MOUNJARO (tirzepatide) is predominantly gastrointestinal, aligning with the incretin receptor agonist class, with frequency and severity correlating to dose and titration speed.[3][4] Most common reactions include nausea, diarrhea, vomiting, abdominal pain, constipation, dyspepsia, and decreased appetite.[3][4] These effects are typically mild-to-moderate, peak during dose escalation, and lessen over time on a stable dose.[3] If tolerability is significantly compromised, providers should consider delaying escalation or extending the current dose interval
Each modification produces a molecule that is meaningfully different from the originator, performs better in some clinical dimension, and cannot be substituted at the pharmacy counter by a biosimilar of the original
3.6.2 Gutbrain axis alterations in stroke Growing evidence reveals that stroke not only disrupts CNS homeostasis but also profoundly alters the MGBA, leading to bidirectional interactions that can exacerbate neuroinflammation and hinder recovery